DiGA for Pharma as Business Growth Opportunity

Type: Expert Panel Discussion

DiGA (German: Digitale Gesundheitsanwendungen) are reimbursable health applications introduced in Germany in 2019, with over 50 added to the official directory since then. Hailed as the future of digital health and a potential model for Europe by industry experts, DiGAs are transforming healthcare with tangible benefits for patients and providers alike.

In this session, we explored how Digital Health Applications (DiGA) can enhance business revenue and drive digital transformation for pharmaceutical companies. The panel brought together experts from various domains, who shared their insights on this important topic. Watch the panel and identify tactics and trends to make your path of integrating DiGA into your business smooth and simple.

Key Highlights

• The Future of Pharma: The significance of digitalization as a groundbreaking approach to addressing patient needs and enhancing research and development (R&D) efforts in the pharmaceutical industry.
• New Revenue Channels and Data-Driven Insights: Defining DiGA as a means for pharmaceutical companies to open new revenue channels. DiGAs enable data-driven insights and enhance patient engagement, leading to improved business opportunities.
• Three Pillars of DiGA Development: Identifying product, technology, and regulatory areas as key points of ensuring successful implementation and utilization of digital health applications.
• Streamlining and Accelerating DiGA Development: Navigating through the requirements set by BfArM (Federal Institute for Drugs and Medical Devices), accelerating all stages of DiGA development, clinical studies, and the certification process.